Delayed-release tablets are oral medications designed with a coating or barrier that prevents the drug from dissolving until it reaches a specific part of the digestive tract, usually the small intestine or colon. The most common version uses an enteric coating, a thin polymer shell that stays intact in the acidic environment of the stomach but dissolves once it encounters the higher pH of the intestine. This design serves two broad purposes: protecting the stomach lining from irritating drugs, and protecting acid-sensitive drugs from being destroyed by stomach acid before they can do any good.
How Enteric Coatings Actually Work
The core idea is straightforward. Your stomach is highly acidic, with a pH somewhere around 1.5 to 3.5. Your small intestine, by contrast, is much less acidic, generally sitting around pH 5.5 to 7. The polymers used in enteric coatings are chosen specifically because they remain solid and impermeable at low pH but begin dissolving once the surrounding pH climbs above a certain threshold. Common coating materials include methacrylic acid copolymers (sold under brand names like Eudragit) and hydroxypropyl methylcellulose acetate succinate. When a coated tablet hits stomach acid, the coating simply sits there, keeping the drug sealed inside. Once the tablet passes through the pyloric sphincter into the duodenum, the rising pH triggers the coating to dissolve, and the drug is released.
The reality in a living body is a bit messier than that clean description suggests. Research has found that the actual rate at which enteric coatings dissolve in the intestine depends not just on pH but also on the concentration of bicarbonate in intestinal fluid. At the relatively low bicarbonate levels found in human intestines, coating dissolution can be considerably slower than what standard laboratory tests predict.1PubMed. Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications This means the neat pH-threshold story told on pharmacy labels is a simplification. The coating does respond to pH, but the local chemistry at the coating surface, including dissolved carbon dioxide and carbonic acid, influences exactly when and how fast the drug escapes.
What Happens After You Swallow One
Once you take a delayed-release tablet, it enters a kind of holding pattern. The drug is locked behind the coating for as long as the tablet sits in your stomach. A study comparing absorption profiles of a delayed-release formulation of divalproex sodium showed no drug absorption at all during the first two hours after dosing. After the tablet cleared the stomach and the coating dissolved in the intestine, roughly 63% of the dose was absorbed in under an hour. Peak blood levels were reached about four hours after dosing, and absorption was essentially complete by six to seven hours.2PubMed. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets — clinical implications That initial dead zone followed by a burst of absorption is the signature pattern of a delayed-release tablet and one of the key ways it differs from an extended-release formulation, which dribbles the drug out slowly over many hours.
That distinction matters practically. If you are switched from a delayed-release version of a medication to an extended-release version (or vice versa), the timing and peak concentration of the drug in your blood can change substantially, even if the total amount absorbed over the day is similar. The same divalproex study found that the extended-release formulation started releasing drug almost immediately but reached full absorption only after more than 20 hours, with no sharp peak at all.2PubMed. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets — clinical implications These are not interchangeable schedules, and switching between them usually requires a dose adjustment from your prescriber.
Why Food Changes the Timing
One of the most underappreciated facts about delayed-release tablets is that eating can dramatically alter when the drug actually reaches your bloodstream. An enteric-coated tablet cannot begin releasing its drug until it leaves the stomach, and your stomach does not empty solid objects on the same schedule as it processes food. Indigestible solids like coated tablets tend to leave the stomach during the “housekeeper wave,” a strong contraction cycle that sweeps debris out between meals. If you take your tablet on an empty stomach, it can clear in roughly 40 minutes on average. But a meal changes the picture entirely. In volunteers who ate a standard breakfast, gastric emptying of an indigestible tablet was delayed to over four hours on average, and the delay tracked closely with the calorie density of the food.3PubMed. Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector If someone grazes through several meals and snacks during the day, the tablet could sit in the stomach until late at night.
This has been confirmed for specific drugs. With enteric-coated aspirin, the lag time before any aspirin appeared in the blood jumped from about 2.7 hours in fasting subjects to nearly 9 hours after a meal. Time to peak concentration stretched from about 8 hours to almost 14 hours.4PubMed. Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time For someone taking daily low-dose aspirin for heart protection, this variability is unlikely to matter much because the drug’s benefit accumulates over days. But for a medication where the timing of each dose matters, like an antibiotic or an anti-seizure drug, that kind of unpredictability can be a real problem. This is why many delayed-release medications include specific instructions about whether to take them with or without food.
Common Drugs That Use Delayed Release
Proton-pump inhibitors like omeprazole and lansoprazole are probably the most familiar example. These drugs shut down acid production in the stomach, but they are themselves destroyed by stomach acid. Without an enteric coating to shepherd them past the stomach intact, they would be broken down before they could reach the intestine and be absorbed into the bloodstream.5PubMed. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations The coating’s job here is purely protective: the drug needs to survive the stomach, not avoid harming it. Formulation research has focused on improving the stability of these coatings using blends of polymers. Combining Eudragit L with hydroxypropyl methylcellulose acetate succinate, for instance, has been shown to improve both the gastric resistance and the chemical stability of lansoprazole pellets compared to single-polymer coatings.6PubMed Central. Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability
Aspirin is the flip side of the coin. The drug itself is stable in acid, but plain aspirin irritates the stomach lining on contact. Enteric-coated aspirin at 100 mg per day caused significantly less gastric and duodenal damage over a week compared to the same dose of plain aspirin in healthy volunteers, with injury levels comparable to a placebo.7PubMed. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions Separate research confirmed that at low doses, the stomach damage from aspirin is largely a local, topical effect rather than a body-wide consequence of the drug blocking prostaglandins, and that enteric coating virtually eliminates that topical injury.8PubMed Central. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis This is why cardiologists often recommend enteric-coated aspirin for patients on long-term daily therapy.
Mesalamine, a drug used to treat inflammatory bowel disease, represents a third scenario. Here the goal is not just to get past the stomach but to deliver the drug specifically to the colon, where the inflammation lives. Formulations for mesalamine use coatings that dissolve at even higher pH thresholds, or combine pH-sensitive coatings with time-dependent barriers. One approach uses a dual system: a core tablet of mesalamine is first surrounded by a time-dependent swelling layer, then encased in a pH-sensitive outer coat.9PubMed. Design, development and optimization of a novel time and pH-dependent colon targeted drug delivery system The outer coat dissolves in the upper intestine, then the inner layer swells slowly for several hours, buying enough time for the tablet to travel further down the gut before releasing mesalamine. A pH-enzyme double-dependent system achieved colon drug concentrations over 2.6 times higher than a simple drug suspension.10PubMed Central. A novel pH-enzyme-dependent mesalamine colon-specific delivery system
Why You Should Never Crush or Split Them
This comes up constantly in clinical practice, particularly with older adults or people who have trouble swallowing. Crushing a delayed-release tablet destroys the coating that controls where and when the drug is released. The result can be a sudden dump of the full dose in the stomach rather than a gradual release in the intestine. For a drug like omeprazole, that means the drug gets destroyed by acid and you get little or no benefit. For aspirin, it means direct irritation of the stomach lining. A systematic review of tablet-splitting practices found that while some sustained-release medications might technically survive being split, the difficulty of knowing which products can and cannot tolerate it, combined with the risk of overly rapid drug release, supports the general rule against splitting any slow-release or delayed-release product.11PubMed Central. Concerns regarding tablet splitting: a systematic review
If you have difficulty swallowing tablets, the better approach is to ask your pharmacist whether a liquid, sprinkle, or orally disintegrating version of the same drug exists. Some delayed-release capsules contain coated granules inside and can be opened and sprinkled onto soft food without losing the delayed-release property, because the coating lives on each individual granule rather than on the capsule shell. But this only works when the manufacturer has designed it that way and says so on the label. Assuming it is safe to open any capsule or crush any tablet is a gamble with unpredictable consequences.
How the Coating Is Applied During Manufacturing
Making a delayed-release tablet is not just about choosing the right polymer. The coating has to be applied uniformly, at the right thickness, and cured properly for it to function. Most enteric coatings are applied using a process called film coating, where a solution or dispersion of the polymer is sprayed onto tablets or pellets tumbling in a rotating drum or fluidized bed. The spraying must be precisely controlled: too fast and the tablets become sticky and clump together; too slow and the coating dries before it can form a smooth, continuous film. Batch-to-batch uniformity of the coating is considered a critical quality attribute, and manufacturers increasingly use computational modeling alongside experimental testing to optimize the process.12PubMed Central. Pharmaceutical Coating and Its Different Approaches, a Review
The choice between water-based and solvent-based coating systems adds another layer of complexity. Water-based (aqueous) coatings are preferred for environmental and safety reasons, but they sometimes require thicker layers to achieve the same acid resistance as solvent-based coatings. The type and amount of plasticizer added to the coating formula also matters: some plasticizers evaporate during the drying step, leaving the film brittle. Research has shown that the choice of plasticizer is especially important for aqueous dispersions, and that applying an undercoat beneath the enteric layer can reduce the total amount of coating material needed.13PubMed. Influence of aqueous coatings on the stability of enteric coated pellets and tablets A coating that looks perfect to the eye can still fail if internal stresses cause microscopic cracks during storage, which is why finished products undergo dissolution testing under standardized acid and buffer conditions.
How Regulators Test Whether the Coating Works
The standard quality-control test for a delayed-release product is a two-stage dissolution test. In the first stage, the tablet sits in an acidic medium (simulating stomach acid) for a set period, typically two hours. If more than a small percentage of the drug leaks out during this stage, the batch fails. In the second stage, the medium is switched to a buffer at higher pH (simulating the intestine), and the drug must now release within a specified time window. The U.S. Pharmacopeia describes two variants of this test. Method A involves adding a concentrated buffer solution directly to the acidic medium; Method B transfers the tablet into a separate vessel of buffer. Imaging studies using fluorescent dyes have confirmed that both methods produce equivalent results for coating dissolution rates, and that the rapid buffer addition in Method A does not create problematic “hot spots” that would artificially speed up the test.14PubMed. Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence
The catch, as noted earlier, is that these tests use simple buffer solutions that do not fully replicate the bicarbonate chemistry of real intestinal fluid. A tablet that passes the standard dissolution test with flying colors in the lab may dissolve more slowly inside a person than the test would predict.1PubMed. Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications This gap between lab performance and real-world performance has pushed researchers to develop more biologically realistic test conditions, though standard pharmacopeial methods have not yet adopted them widely.
Newer Approaches to Targeted Gut Delivery
The classic pH-sensitive coating works well for getting a drug past the stomach and into the upper intestine, but it has limits. The pH profile along the gut is not a clean, steadily rising gradient. In inflammatory bowel disease, local pH in the colon can be lower than normal, potentially causing a pH-sensitive coating to dissolve too late or not at all. Researchers are now developing delivery systems that respond not just to pH but to signals unique to specific regions of the gut, particularly the enzymes produced by resident bacteria. Natural polysaccharides like pectin, chitosan, and guar gum are being explored as coating materials because they resist digestion in the stomach and small intestine but are broken down by microbial enzymes in the colon.15PubMed. Microbiota-sensitive drug delivery systems based on natural polysaccharides for colon targeting By combining a bacteria-sensitive material with a pH-dependent or time-dependent outer layer, these systems aim to be more reliable than any single trigger alone.
A broader category of research under the umbrella of microbiome-active drug delivery systems is exploring designs that respond to enzyme activity, metabolite concentrations, biofilm presence, and even receptor signals in microbial environments. These platforms are being investigated for infectious diseases, inflammatory conditions, and metabolic disorders.16PubMed. Microbiome-active drug delivery systems (MADDS): Leveraging microbial stimuli for controlled drug release None of these have replaced the workhorse enteric coating in mainstream pharmacy yet, but they represent a meaningful shift in thinking: from “protect the drug from the stomach” to “deliver the drug precisely where the disease is.”
The Commercial Side of Delayed-Release Formulations
It would be naive to discuss delayed-release tablets purely in terms of clinical benefit. Reformulating an existing drug into a new delivery system is one of the most common strategies pharmaceutical companies use to extend the commercial life of a product. When a brand-name drug’s original patent nears expiration, the manufacturer may develop a delayed-release or extended-release version, patent the new formulation, and continue marketing a branded product for years after generic versions of the original become available.17PubMed. How drug life-cycle management patent strategies may impact formulary management Analysis of U.S. pharmaceutical data has shown that dosage forms requiring advanced manufacturing technology, including delayed-release and extended-release tablets, have significantly extended product life cycles over the past two decades, and that formulation-related patents contribute meaningfully to that extension.18Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. Effects of new formulation strategy on life cycle management in the US pharmaceutical industry
This does not mean every delayed-release reformulation is a cynical patent play. Plenty of these products genuinely improve tolerability, adherence, or dosing convenience. But when your doctor switches you from a cheap generic immediate-release tablet to an expensive brand-name delayed-release version, it is worth asking whether the clinical advantage justifies the cost difference, or whether the new formulation exists primarily to keep a revenue stream alive. Pharmacists and formulary managers increasingly scrutinize these switches for exactly that reason.